The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Fu, Zeze ^a   Deng, Biyong ^a   Liao, Yuxin ^a   Shan, Liancheng ^a,b   Yin, Fei ^a   Wang, Zhuoying ^a   Zeng, Hui ^a   Zuo, Dongqing ^a   Hua, Yingqi ^a   Cai, Zhengdong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Metastasis; Necroptosis; Osteosarcoma; RIP1; RIP3; Shikonin

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE INHIBITOR; NECROSTATIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE INHIBITOR; RECEPTOR INTERACTING PROTEIN 1; RECEPTOR INTERACTING PROTEIN 3; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SHIKONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL CYCLE; CELL DEATH; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NECROPTOSIS; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; NECROSIS; NEOPLASM TRANSPLANTATION; NUCLEAR PORE COMPLEX PROTEINS; OSTEOSARCOMA; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; UP-REGULATION;

EID: 84889032526     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-580     Document Type: Article

References (36)

1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004, 54(2):94-109. 10.3322/canjclin.54.2.94, 15061599.
2. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr 2009, 21(3):365-372. 10.1097/MOP.0b013e32832b1111, 19421061.
3. Caudill JS, Arndt CA. Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev 2007, 18(1):62-78. ix.
4. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9(4):422-441. 10.1634/theoncologist.9-4-422, 15266096.
5. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011, 28(5):493-503. 10.1007/s10585-011-9384-x, 3081058, 21461590.
6. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18(11):1272-1282. 10.1101/gad.1199904, 420353, 15145826.
7. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005, 1(2):112-119. 10.1038/nchembio711, 16408008.
8. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008, 4(5):313-321. 10.1038/nchembio.83, 18408713.
9. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009, 137(6):1100-1111. 10.1016/j.cell.2009.05.021, 19524512.
10. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science (New York, NY) 2009, 325(5938):332-336.
11. Hu X, Han W, Li L. Targeting the weak point of cancer by induction of necroptosis. Autophagy 2007, 3(5):490-492.
12. Singh B, Sharma MK, Meghwal PR, Sahu PM, Singh S. Anti-inflammatory activity of shikonin derivatives from Arnebia hispidissima. Phytomedicine 2003, 10(5):375-380. 10.1078/0944-7113-00262, 12834001.
13. Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, Li S, Wen G, Zhang C, Dong W, et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol 2011, 658(2-3):242-247. 3299007, 21392503.
14. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007, 6(5):1641-1649. 10.1158/1535-7163.MCT-06-0511, 17513612.
15. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009, 14(5):674-686. 10.1007/s10495-009-0334-x, 19288276.
16. Park S, Shin H, Cho Y. Shikonin induces programmed necrosis-like cell death through the formation of receptor interacting protein 1 and 3 complex. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2013, 55:36-41.
17. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011, 30(42):4297-4306. 10.1038/onc.2011.137, 21516121.
18. Chen C, Shanmugasundaram K, Rigby AC, Kung AL. Shikonin, a natural product from the root of Lithospermum erythrorhizon, is a cytotoxic DNA-binding agent. Eur J Pharm Sci 2013, 49(1):18-26. 10.1016/j.ejps.2013.02.003, 23422689.
19. Wu H, Xie J, Pan Q, Wang B, Hu D, Hu X. Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PloS one 2013, 8(1):e52706. 10.1371/journal.pone.0052706, 3536779, 23300986.
20. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000, 18(3):261-271. 10.1023/A:1006767007547, 11315100.
21. Huang C, Luo Y, Zhao J, Yang F, Zhao H, Fan W, Ge P. Shikonin Kills Glioma Cells through Necroptosis Mediated by RIP-1. PloS one 2013, 8(6):e66326. 10.1371/journal.pone.0066326, 3695975, 23840441.
22. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137(6):1112-1123. 10.1016/j.cell.2009.05.037, 2727676, 19524513.
23. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, Damko E, Moquin D, Walz T, McDermott A, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012, 150(2):339-350. 10.1016/j.cell.2012.06.019, 3664196, 22817896.
24. McComb S, Cheung HH, Korneluk RG, Wang S, Krishnan L, Sad S. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ 2012, 19(11):1791-1801. 10.1038/cdd.2012.59, 3469059, 22576661.
25. Moujalled DM, Cook WD, Okamoto T, Murphy J, Lawlor KE, Vince JE, Vaux DL. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis 2013, 4:e465. 10.1038/cddis.2012.201, 3563989, 23328672.
26. Chang IC, Huang YJ, Chiang TI, Yeh CW, Hsu LS. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol Pharm Bull 2010, 33(5):816-824. 10.1248/bpb.33.816, 20460760.
27. Rhim JS, Putman DL, Arnstein P, Huebner RJ, McAllister RM. Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine. Int J Cancer 1977, 19(4):505-510. 10.1002/ijc.2910190411, 265298.
28. Hensler PJ, Annab LA, Barrett JC, Pereira-Smith OM. A gene involved in control of human cellular senescence on human chromosome 1q. Mol Cell Biol 1994, 14(4):2291-2297. 10.1128/MCB.14.4.2291, 358595, 8139534.
29. Chang PC, Li M. Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor. J Virol 2008, 82(1):278-290. 10.1128/JVI.01552-07, 2224387, 17942552.
30. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 2003, 196(1):9-18. 10.1002/jcp.10256, 12767037.
31. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23(16):2934-2949. 10.1038/sj.onc.1207515, 15077155.
32. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005, 205(2):275-292. 10.1002/path.1706, 15641020.
33. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6(7):1075-1085. 10.1586/14737140.6.7.1075, 16831079.
34. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rec Cancer 2002, 2(4):277-288.
35. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 2010, 9(3):731-741. 10.1158/1535-7163.MCT-09-0147, 2837364, 20197388.
36. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 2010, 28(6):766-782. 10.1007/s10637-009-9311-z, 19730790.